Carvedilol
Product Images NDC 53808-1024

4 FDA label images from State Of Florida Doh Central Pharmacy · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 53808-1024). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image For 12.5mg (Carvedilol 12.5mg)

Label Image For 12.5mg (Carvedilol 12.5mg)
Carvedilol 12.5 mg tablets label showing a quantity of 30 tablets. The label includes the lot number 13DP005A, expiration date of 07-24-2014, and indicates the product is prescription only. Packaged by DOH Central Pharmacy, Tallahassee, FL 32304, State of Florida DOH Central Pharmacy. UPC barcode visible at the bottom.*
FDA Label Image

Structural Formula (B6e3821c Bea7 47fd A9f4 6769ed16f46d 01)

Structural Formula (B6e3821c Bea7 47fd A9f4 6769ed16f46d 01)
Chemical structure of carvedilol showing its molecular framework, including a carbazole moiety linked to a side chain with hydroxyl and methoxy-substituted phenyl groups.*
FDA Label Image

Figure 1 (B6e3821c Bea7 47fd A9f4 6769ed16f46d 02)

Figure 1 (B6e3821c Bea7 47fd A9f4 6769ed16f46d 02)
A survival analysis line graph comparing mortality percentages over 24 months for Carvedilol versus Placebo in an intent-to-treat population. The x-axis shows months, and the y-axis shows percent mortality. Two lines represent Carvedilol and Placebo, with Placebo showing higher mortality. A p-value of 0.03 is noted on the graph.*
FDA Label Image

Figure 2 (B6e3821c Bea7 47fd A9f4 6769ed16f46d 03)

Figure 2 (B6e3821c Bea7 47fd A9f4 6769ed16f46d 03)
A forest plot titled 'Effects on Mortality for Subgroups in CAPRICORN,' showing hazard ratios for various subgroups related to cardiac conditions. Groups include age, gender, timing of randomization, prior use of beta-blockers, Killip class, thrombolytic therapy, PTCA for myocardial infarction, presence of congestive heart failure, use of diuretics, angina, hypertension, diabetes, heart rate, and systolic blood pressure. The x-axis represents hazard ratios ranging from 0.4 to 1.3, with points and confidence intervals depicted for each subgroup.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.